United States: FTC Merger Challenge Based On Harm To Potential Competition Rejected By District Court

Last Updated: September 30 2015
Article by Bruce D. Sokler and Farrah Short

In what has become rare of late, the Federal Trade Commission ("FTC") suffered a litigation loss in a merger case with a district court's denial of a preliminary injunction to block the deal pending administrative litigation. FTC v. Steris Corporation, 1:15-cv-01080 (N.D. Ohio September 24, 2015). The FTC's case was based on the "actual potential entrant" doctrine which focuses on harm to likely future competition—differing from traditional merger challenges based on harm to direct current competition. Assuming the infrequently used and often challenged doctrine as valid for preliminary injunction purposes, the district court found that the FTC failed to show that the target company probably would have entered the relevant market as a new competitor but for the proposed merger.

Last October, Steris Corporation ("Steris"), an Ohio-based maker of hospital sterilization products, agreed to buy Synergy Health plc ("Synergy"), a provider of sterilization services for medical-device manufacturers, hospitals and other industries based in England for $1.9 billion. Steris and Synergy are the second- and third-largest sterilization companies in the world. Sterigencis International LLC ("Sterigencis") is the largest. Sterilization is the critical final step in the manufacture of many healthcare-related products, required by the Food and Drug Administration to ensure the products are free of unwanted microorganisms. The majority of sterilization is outsourced by the manufacturers to companies like Steris and Synergy. While there are three contract sterilization methods currently used in the U.S., gamma sterilization is the most effective and economical option for healthcare products. Steris and Sterigencis together account for approximately 85% of all U.S. contract sterilization services.

Synergy is the largest provider of one of the other methods of sterilization in the U.S., and operates many gamma facilities outside the United States. Synergy also operates an x-ray sterilization facility in Switzerland—the only facility in the world providing x-ray sterilization services on a commercial scale. X-ray sterilization could provide a competitive alternative to gamma sterilization, but is not currently available in the United States. In 2013, Synergy began investigating the possibility of establishing an x-ray sterilization facility in the United States.

The FTC's Theory

The FTC concluded after its investigation of the proposed transaction that it would violate Section 7 of the Clayton Act, and in May sought injunctive relief under Section 13(b) of the Clayton Act.1 Section 13(b) authorizes a court to grant a preliminary injunction if the FTC raises "questions going to the merits so serious, substantial, difficult and doubtful as to make them fair ground for thorough investigation, study, deliberation and determination by the FTC."

Under the actual potential entrant doctrine, "the FTC asserted that the acquisition of an actual potential competitor violates Section 7 if (1) the relevant market is highly concentrated, (2) the competitor 'probably' would have entered the market, (3) its entry would have had pro-competitive effects, and (4) there are few other firms that can enter effectively."

The District Court's Decision

The case law on potential competition is somewhat dated and sparse, and the merging parties asserted that the actual potential entrant doctrine is disfavored. Nonetheless, for purposes of the preliminary injunction motion, the district court assumed its validity. The district court directed the parties to focus on the second prong: "whether, absent the acquisition, the evidence shows that Synergy probably would have entered the U.S. contract sterilization market by building one or more x-ray facilities within a reasonable period of time."

The district court concluded that the FTC failed to carry its fact-based burden.

The opinion recapped in detail the evidence surrounding Synergy's efforts to establish an x-ray sterilization facility in the United States. The key dispute between the FTC and the merging parties was not about whether Synergy pursued such a business strategy—they agreed that it did—but rather they disputed why Synergy abandoned the effort. The merging parties argued that the strategy was abandoned because Synergy concluded that "there was no reasonable prospect of customer acceptance for Synergy's X-ray project." The FTC countered that Synergy was poised to enter the U.S. market in 2014, and only abandoned its plan because of the pending merger with Steris.

The district court delved into the factual record established in the three-day hearing and found that Synergy abandoned its U.S. x-ray plan due to legitimate business reasons separate from the planned merger, and thus the FTC failed to show that absent the merger Synergy probably would have entered the U.S. contract sterilization market by building x-ray facilities. First, the court held that the most significant reason for discontinuing Synergy's U.S. x-ray plan was lack of customer commitment. The district court found that not a single customer, despite significant effort by Synergy, was willing to provide the financial commitment necessary to build the x-ray facility. Second, the evidence showed that the customers' concerns were due to the significant cost of converting to a new method of sterilization without any significant benefit in x-ray sterilization over other methods. Third, Synergy was unable to obtain business approval internally for the capital costs to build the x-ray facilities. The investment would have consumed Synergy's entire discretionary budget, thus little risk would be tolerated by the company to pursue the plan. Fourth, the district court also found the sequence of the timing of the merger announcement and the abandonment of the x-ray plan was evidence supporting the merging parties' argument. The district court reasoned that the fact that Synergy continued to pursue its x-ray strategy after the merger was announced and only subsequently abandoned it "may actually be the best evidence that it was done for legitimate business reasons, as opposed to anti-competitive ones." The district court elaborated that had Synergy terminated its U.S. x-ray project when it began merger negotiations with Steris or when the merger was announced, it might have viewed the evidence differently.

While the FTC has not recently suffered a litigation loss in a merger challenge, this case does not necessarily suggest a weakening in its merger enforcement efforts. Potential competition cases are arguably more difficult to win than traditional merger cases. As was seen here, they are heavily fact-dependent, and the FTC cannot rest on structural evidence and the Philadelphia National Bank presumption of harm from concentration increases in a narrowly defined market. And perhaps of value to the FTC here, is its ability to walk away without the actual potential entrant doctrine having been challenged by the district court.

This case also serves as an illustration of the appropriate conduct merging parties should adhere to pre-close. Synergy and Steris won here because Synergy actively continued to operate its business as usual despite the pending merger, including pursuing its competitive business strategies. Had Synergy abandoned its U.S. x-ray plans because of the proposed merger, not only would the FTC have likely won its preliminary injunction motion, but the parties might have faced an antitrust "gun jumping" challenge as well. Under the antitrust laws, merging competitors must continue to operate and vigorously compete with each other until the transaction closes. Synergy and Steris appeared to do just that.

Footnote

1. http://www.mintz.com/newsletter/2015/Advisories/4992-0615-NAT-AFR/

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Bruce D. Sokler
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions